News

Martin Lehr 6/2/25 Martin Lehr 6/2/25

CTIM-76 Trial in Progress - ASCO 2025

A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors

Roisin E. O’Cearbhaill, Minal Barve, Christopher J. Darus, Nashat Gabrail, Paul Johannet, Jade Loh, MaryBeth LeRose, Angela Jain, Martin Gutierrez, Michael J. Birrer

American Society of Clinical Oncology I Annual Meeting I Abstract TPS2685 I May 30-June 3, 2025

Martin Lehr 4/28/25 Martin Lehr 4/28/25

Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3

Stanley Roberts, Kelly Byrnes-Blake, and Eric Butz

American Association for Cancer Research I Annual Meeting I Abstract 4884 I April 26-30, 2025

Martin Lehr 11/9/24 Martin Lehr 11/9/24

Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6

Kelly Byrnes-Blake, Edward Calamai, Stanley Roberts, and Eric Butz

Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting I Abstract 1288 I November 7-11, 2024